ArticleTranslational lung cancer research2023

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis.

Wenjie Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.